By defining molecular determinants and regulatory nodes in the PINK1/Parkin pathway, the paper highlights actionable targets and mechanisms for drug discovery, biomarker development, and therapies aimed at restoring mitochondrial quality control in Parkinson's disease.

Useful clinically because it highlights an immune‑mediated mimic of a Parkinsonian postural deformity and responsiveness to B‑cell immunotherapy, but offers limited direct mechanistic or broad therapeutic discovery insight for Parkinson's disease.

Provides actionable, translationally relevant targets and delivery strategies (LAT1-targeting, site-specific chelation, ferroxidase biomarkers, glutathione/ATP readouts) that could be prioritized for neuroprotective therapeutic development and repurposing in Parkinson's disease.

H4R is a druggable GPCR with existing ligands, so resolving its cell- and disease-stage specific signaling bias could enable repurposing or development of H4R-targeted therapies to modulate neuroinflammation and potentially protect dopaminergic neurons in Parkinson's disease.

It surfaces a diverse set of marine natural-product leads acting on neuroinflammation and oxidative-stress pathways relevant to PD—valuable for early-stage lead discovery and hypothesis generation—while being a review limits direct, immediate translational action.

By linking age-related loss of butyrate-producing microbes to PD-associated dysbiosis, the paper highlights microbial metabolites and restoration of butyrate producers as actionable therapeutic targets and important factors for patient stratification in microbiome-directed interventions.

By outlining practical delivery platforms and rational design levers to get targeted degraders into the brain, the paper provides actionable direction for developing PROTAC strategies against Parkinson's-relevant, otherwise hard-to-drug targets such as alpha-synuclein and other neurodegeneration…

Provides a useful translational overview to guide prevention-focused trial design and risk‑stratified interventions, but offers limited mechanistic or molecular targets for immediate drug-discovery translation.

The paper flags isoquinolines as attractive lead chemotypes for Parkinson's drug discovery due to multitarget enzyme modulation, providing medicinal chemistry direction while emphasizing the need for BBB, pharmacokinetic, safety, and in vivo efficacy studies for translation.

Provides moderate translational value as supportive, low-risk symptomatic therapy for PD-related hypokinetic dysarthria and guidance to combine singing with established voice therapy (LSVT), but offers little mechanistic or disease-modifying insight for therapeutic discovery.

The results implicate neurovascular unit dysfunction and cerebral small vessel disease as potential contributors or biomarkers in PD—offering a rationale for imaging-based stratification and exploration of vascular- or clearance-targeted interventions—though evidence is low quality and largely…

Because hyposmia is a common prodromal feature of Parkinson's disease, the review's aggregation of imaging correlates (including dopaminergic deficits on DAT imaging and consistent orbitofrontal involvement) highlights candidate neuroimaging biomarkers that could help identify and stratify…

By cataloguing biomarkers and mechanistic rationales for antidiabetic agents in PD, the paper helps prioritize measurable endpoints for disease‑modification trials and highlights methodological gaps whose resolution could accelerate repurposing efforts.

Provides a translational framework for tailoring PD therapeutics to disease-specific BBB changes and improving delivery approaches, but remains a review with limited PD-specific mechanistic or actionable therapeutic leads.

BBB-targeted nanotechnology could materially improve delivery of neuroprotective or disease-modifying therapies and mitigate inflammation/oxidative stress relevant to PD, offering translational promise despite the review's broad scope and limited clinical/safety detail.

This report has minimal direct value for Parkinson's therapeutic discovery but is clinically relevant by highlighting diagnostic challenges and the need to consider opportunistic fungal CNS infections in immunocompromised patients with PD, which could affect patient management rather than drug…

Human stem cell platforms improve translational relevance for mechanistic studies and target validation (inflammation, α-synuclein, mitochondria) and identify environmental modifiers (micro/nanoplastics) that could guide novel intervention targets or risk-reduction strategies.

Intranasal SLNs offer a translationally promising route to bypass the BBB and deliver neuroprotective or disease-modifying agents to the brain for Parkinson's, but the paper is a broad delivery-focused review with little Parkinson-specific mechanistic or efficacy data.

It identifies actionable molecular targets and biomarker directions (m6A enzymes/readers linked to dopaminergic vulnerability and synaptic dysfunction) that could open novel therapeutic or diagnostic paths for Parkinson's, although most data remain correlative and require causal, cell-type-specific…

Provides mechanistic convergence (α‑synuclein seeding, mitochondrial toxin exposure, inflammation, ENS‑vagal spread) that highlights the ENS as a tractable axis for exposure reduction, biomarker development, and therapeutic targeting, though translational actionability is limited by reliance on…

By highlighting a minimally invasive, scalable biomarker for early and preclinical identification and enrichment of at-risk cohorts, the work supports better patient selection and outcome measures for disease‑modifying PD trials and accelerates translational therapeutic development.

By identifying modifiable lifestyle factors, potential neuroimaging markers, and methodological pathways to quantify reserve, the paper highlights avenues for prognostic biomarker development and stratified intervention strategies that could inform therapeutic discovery, though it does not provide…

Signals subtle yet clinically relevant declines in muscle mass and function in mild-to-moderate PD that can guide rehabilitation, nutritional interventions, and selection of trial endpoints for mobility/fall prevention, though it provides limited direct molecular targets for drug discovery.

Provides an actionable, disease-relevant mechanism linking Parkin to inflammasome regulation and identifies NLRP3 inhibition and CMA activation as translatable therapeutic strategies with preclinical in vivo support for Parkinson's disease.

By providing a drug-like activator of Parkin with both cellular and in vivo neuroprotective effects against α-synuclein-driven pathology, the work presents a actionable, translational strategy for disease-modifying Parkinson's therapeutics.